Blood donors and the RBCs and other components they willingly provide are essential in the delivery of healthcare in all parts of the world. Nearly 70% of donated blood comes from repeat or committed donors. The amount of iron removed in the 10 min or so it takes to withdraw a unit of blood (500 ml, plus 25 ml for testing) requires over 24 weeks to replace on a "standard" diet, i.e., without added iron in the form of supplements The cumulative effect of repeat blood donations without adequate iron replacement or a longer wait between donations results in iron deficiency (ID) in many donors, low haemoglobin deferral (~8% of donation attempts), and frank anaemia in some. Moreover, ID can be associated with side effects that can impact a blood donor's health, such as fatigue, cognitive changes and other neuromuscular symptoms. In an effort to better identify and prevent ID, blood collection agencies are recommending various strategies, including changes in the donation interval, donation frequency, testing of iron status and iron supplementation. In this review, we present the evidence basis for these strategies and suggest our own approaches to improving iron balance in blood donors.
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Iron deficiency (ID) is endemic in blood donors, affecting 25-35% of all red blood cell (RBC) donors with higher prevalence associated with female sex, younger age (in females), increasing blood donation frequency and shorter interval since last donation. (Cable et al, 2012a; Rigas et al, 2014) High prevalence rates are seen in blood donors worldwide, despite rational attempts in some jurisdictions to lessen the risk by setting higher pre-donation haemoglobin (Hb) cut-offs, reducing the frequency of donation or restricting the annual limit on the number of times blood donation is permitted (Goldman et al, 2016a) . Likewise, the decades-old approach of advising donors to consume iron-rich foods has been an ineffective strategy to ameliorate this condition.
Calls to address ID in blood donors have been made for decades and there has always been a societal expectation that blood collectors should advocate for donor health, given the altruistic, voluntary nature of a blood donation (Bianco et al, 2002; Newman, 2006) . So, why has this issue of mitigating ID in blood donors resurfaced now? First, new information from large-scale studies has confirmed the high prevalence of ID and the subgroups at risk. Second, recent studies have focused attention on the potential adverse effects of ID, particularly non-anaemic ID. Most importantly, controlled trials have refined the dose-response benefits of iron supplementation, and the potential effectiveness of strategies to improve iron balance. While these studies have closed many of the scientific gaps, other, chiefly operational issues remain to be fully worked out. In the US and a few other countries, high school-aged donors are one of the fastest growing donor subgroups, with 15% of the blood supply in the US now being donated by teenagers (Goldman et al, 2017a) , and new information has highlighted the potential impact of ID on adolescent brain development (Jahanshad et al, 2012) . Forty-three US states allow donation by 16-year-olds; given that 16-to 18-year-olds are still maturing physically and cognitively (Gogtay et al, 2004) , the donor and public health implications of ID in young individuals are considerable. Maintaining donor health and vitality, as well as patient safety, are key goals for blood collectors and for public health. On top of (or because of) these concerns, increased regulatory attention has been focused on ID in blood donors (US Food and Drugs Administration (FDA) 2016).
Imbalance between donation-related iron losses and recovery ferritin) that is held in reserve for erythropoiesis and metabolic use. Cook and Skikne (1982) estimated tissue iron stores of 776 AE 313 mg in men and 309 AE 346 mg in women aged 20-45 years old. Similar estimates have been found in first-time (FT) blood donors, with men having an average of 881 mg storage iron, women ≥50 years having 591 mg, and women 18-50 years having 411 mg . The loss of roughly 250 mg of iron with each whole blood donation, along with the limited stores and capacity for iron absorption, leads to a high incidence of ID in frequent donors, particularly women (Figs 1, 2) . Progressive stages of ID are recognized, beginning with the loss of storage iron, followed by the development of iron-deficient erythropoiesis (IDE), ultimately leading to iron deficiency anaemia (IDA) (Fig 3; Suominen et al, 1998) . Measurement of Hb is a poor surrogate for iron depletion because anaemia is a late manifestation of ID. Moreover, the capillary (fingerstick) Hb minimum threshold intended to protect donors from becoming anaemic (as well as screen out those with disease that may be problematic for transfusion recipients) overestimates venous Hb, especially in iron deficient donors, with the unintended consequence of worsening anaemia in some donors who are already anaemic (Cable et al, 2012b) .
Iron absorption
Absorption of dietary iron by enterocytes in the duodenum and proximal jejunum is tightly regulated. There is no defined mechanism of excretion other than passive losses via the gastrointestinal (GI) tract and skin. Non-haem iron from plant sources comprises the largest proportion of dietary iron, approximately 85-90% of total intake. However, most non-haem iron in vegetables, fruits and grains exists in the ferric state (Fe3 + ) complexed with phytates and tannates, and is less bioavailable (lower fractional absorption) than haem iron from animal sources. Absorption capacity increases in relation to the severity of ID, from 1Á0 mg/day in men (~1Á5 mg/day in menstruating women), to an average of 4-5 mg/day in frequent blood donors (Garry et al, 1995; Kiss et al, 2017) , and is enhanced with supplemental iron (Moretti et al, 2015) . Hepcidin, a peptide hormone that responds rapidly (within hours) to iron levels and erythropoietic signals, serves as the central regulator of iron absorption and release of iron from storage sites through degradation of The greatest proportionate loss (60%) is in women ≤50 years of age.
Fig 2.
Total Body Iron (TBI) estimates in First-time/Reactivated blood donors (FT/RA), repeat donors, and donors deferred for low fingerstick Hb (<125 g/l in both males and females). TBI (Total Body Iron) = RBC iron plus Iron stores . Repeat donors have a partial iron deficit in iron stores, whereas deferred donors have a complete deficit in iron stores, negative iron balance and loss of RBC iron, resulting in anaemia (see Fig 3) . (Girelli et al, 2016) . In ID, hepcidin synthesis decreases, permitting ferroportin to shift iron out of enterocytes, hepatic and other cellular depots, to be shuttled by circulating transferrin for uptake via transferrin receptors located on early erythroid and other nucleated cells.
Acid-blocking drugs interfere with dietary iron absorption (Hutchinson et al, 2007) . Hydrogen ions adjacent to the gastric mucosa facilitate reduction of complexed ferric (Fe3  + ) iron to absorbable ferrous (Fe2 + ) ions. A recent study found that 20% of blood donors take acid blockers in some form; these individuals had modestly, but significantly lower iron stores than non-antacid takers . Oral iron directly stimulates hepcidin production in a dose-dependent manner, not only decreasing the fractional absorption of higher doses of iron (e.g., tablets containing 60 mg elemental iron, especially when taken several times per day) (Moretti et al, 2015; Schrier, 2015) , but increasing GI side effects and noncompliance (Tolkien et al, 2015) . In this regard, supplemental iron provided to blood donors in low doses, e.g., 19-38 mg elemental iron daily , appears to be ideally suited to optimize absorption, minimize side effects and maintain iron balance.
Adverse effects of iron depletion
ID has been associated with a number of adverse clinical effects including fatigue, impaired exercise tolerance, cognitive dysfunction, adverse pregnancy outcomes (perinatal mortality, preterm delivery, low birth weight, newborn cognitive abnormalities), pica (craving and consumption of nonfood substances), restless leg syndrome, and sensorineural hearing loss. Studies reporting the association of ID with adverse outcomes are numerous but there are few rigorous randomized, controlled trials (RCTs), particularly in the population of interest -healthy blood donors. Many studies are confounded by the effects of genetic and developmental factors, socioeconomic status and health conditions, all of which can affect dietary iron access, absorption and loss. In addition, blood donors tend to have non-anaemic iron deficiency (NAID) or very mild IDA in contrast to the more severe IDA studied in publications reporting associations.
Several studies of oral and intravenous iron repletion have shown that female patients with NAID presenting to their physician complaining of chronic fatigue benefit from iron repletion (Verdon et al, 2003; Krayenbuehl et al, 2011; Vaucher et al, 2012) . However, one short-term study in female blood donors provided with daily iron or a placebo found no clinically significant effect on fatigue, depression, exercise performance or quality of life (QoL) scores when tested at 4 weeks after donating . In a larger cross-sectional study of more than 16 000 blood donors, lower iron status was not accompanied by lower physical or mental QoL scores (Rigas et al, 2015) . And, the even larger prospective INTERVAL study that randomized donors in the UK to standard (12 weeks in men, 16 weeks in women) or more frequent intervals found no significant differences in QoL, physical, or cognitive changes across groups, however, they did note more physical donation symptoms (e. g., tiredness, short of breath, restless legs), and lower Hb and ferritin values in the donors who donated in the more frequent groups (DiAngelantonio et al, 2017) It is important to note that QoL and fatigue scores are subject to accommodation, meaning that donors may adjust their activity levels as they become progressively iron depleted and may not notice the accommodation until after iron supplementation, which was not part of either study.
A recent meta-analysis found that a standard blood donation was associated with a small but measurable reduction in exercise performance in the first 2 days after donation, perhaps partly related to decreased blood volume (Remoortel et al, 2017) . Several studies also suggest that individuals with NAID, exercised to exhaustion, demonstrate improved endurance and aerobic performance after iron therapy (Brownlie et al, 2002 (Brownlie et al, , 2004 Brutsaert et al, 2003; Hinton & Sinclair, 2007; Hinton et al, 2008; Dellavalle & Haas, 2014) . Post-donation exercise impairment in NAID may be due to a combination of the relative reduction in Hb, and/or reduced oxidative efficiency from the depletion of tissue iron.
Fourteen RCTs studying cognition in children, adolescents and women were identified in a 2010 systematic review; no RCTs were conducted in men or older individuals (Falkingham et al, 2010) . In anaemic groups, supplementation improved attention, concentration and intelligence, but had minimal effect on non-anaemic participants and no effect on memory, psychomotor skills or scholastic achievement in either group. Blood collectors recruit and draw adolescents who are iron replete or have NAID; occasionally, some eligible teenagers develop post-donation IDA. In non-donors, measures of educational attainment in NAID relative to iron replete individuals for both language and mathematics skills have not been shown to be statistically significantly different (Pratt & Khan, 2015) . Despite inconclusive results examining effects of NAID on adolescent cognition, this is a period of significant brain development involving the myelination of important cortical association areas. Concern around nonreversible impairment, even small difficult-to-measure changes, suggests that steps should be taken to prevent iron depletion in persons whose brains are continuing to undergo detectable remodeling and growth through their early 20s (Casey et al, 2011; Mills et al, 2014; Luna et al, 2015) .
IDA during pregnancy has been compellingly associated with an increased risk of low birth weight, preterm delivery and perinatal mortality (American College of Obstetricians & Gynecologists (ACOG) (2008) . These effects in NAID are not as clearly associated. Accordingly, ACOG (2008) recommends routine screening for anaemia, but not ID. Reassuringly, a recent large retrospective cohort study of blood donors in Quebec found no association between the frequency of blood donation in the 2 years preceding delivery and low birth weight, preterm delivery or stillbirth (Germain et al, 2016) . Neonatal IDA is strongly associated with adverse neurophysiological and neurocognitive outcomes while the effect of NAID on late fetal and early childhood brain development is not fully known (McCann & Ames, 2007) . In women without anaemia, low ferritin values correlate with lower (but not iron-deficient) neonatal ferritin concentrations (Lozoff & Georgieff, 2006) , which could increase vulnerability to nutritional deficiency in the critical first 2 years of life when brain development is most rapid.
Of the reported adverse effects of ID, pica is the one most strongly associated with NAID as well as IDA. Two seminal trials in blood donors note both the increased incidence of pica in women with NAID/IDA as well as symptom reversibility with oral iron therapy (Bryant et al, 2013; Spencer et al, 2013) . The weak association of ID and restless leg syndrome (RLS), an uncomfortable movement disorder of the legs, appears to be primarily in male donors with IDA and is inconsistently reversible with iron therapy, perhaps because RLS results from primary central nervous system abnormalities as well as secondary forms, only some of which appear to be affected by iron balance (Ulfberg & Nystrom, 2004; Bryant et al, 2013; Spencer et al, 2013) . The newest reported association of ID is with sensorineural hearing loss (SNHL). Reported with IDA, the mechanism is unknown, but, in animal models, sudden SNHL is the result of cochlear defects, possibly ischemic in nature (Chung et al, 2014; Schieffer et al, 2017a,b) .
Frequency and predictive factors for id in blood donors
ID is quite common in the general population in many countries, especially among premenopausal women. National epidemiological surveys reveal that 14% of women aged 12-49 years in the US population have ferritin (F) values <15 lg/l (Centers for Disease Control and Prevention 2012). There is fairly good agreement on the frequency of ID based on large-scale studies in blood donors, with FT or "new" blood donors reflecting comparable prevalence to general population estimates. ID in FT, or even "infrequent" (Rigas et al, 2014) male donors (defined as F < 12 lg/l or <15 lg/l) is rare, and ranges from 0% to 1Á3%. (Cable et al, 2011; Salvin et al, 2014) The average prevalence of ID in FT female donors of all ages was 6Á4% in a US study (F ≤ 12 lg/l) and 6Á3% in Australia (F ≤ 15 lg/l). In a study from Denmark stratified by age, 1Á1% of postmenopausal women had F ≤ 15 lg/l (similar to males), whereas the proportion rose to 18Á5% in premenopausal women, similar to the US general population figure in young women cited above (Rigas et al, 2014) .
Nearly 70% of the 6Á85 million blood donors who donated in the US in 2013 are "regular" or repeat donors who are especially prone to ID from progressive blood loss (Whitaker et al, 2016) . The prevalence of ID reported in repeat male donors in the US was 16Á4% (using F ≤ 12 lg/l) (Cable et al, 2011) and ranged from 9Á0% to 14Á3% using F ≤ 15 lg/l (Baart et al, 2013; Rigas et al, 2014; Salvin et al, 2014) . In repeat US female donors, prevalence rates were 27Á1% using F ≤ 12 lg/l and 26Á4% using F ≤ 15 lg/l. Preand postmenopausal female ID was reported in 38Á7% and 21Á7%, respectively using a 15 lg/l cut-off in the Danish cohort (Rigas et al, 2014 ). Higher prevalence rates were reported in two studies using higher ferritin thresholds for low iron. In a US study that used the log soluble transferrin receptor (sTfR)/ferritin ≥2Á07 as the cut-off value for IDE (equivalent to ferritin concentration of 26Á7 lg/l), ID was detected in 2Á5% FT males (by definition, since the threshold was based on 97Á5% cut-off in male FT donors) and 24Á7% females; in the repeat donors, nearly 50% of the males and two-thirds of the females had evidence of ID (Cable et al, 2011) . Higher rates of ID were found using a sensitive higher threshold criterion (F ≤ 25 lg/l) in a large Canadian study (Goldman et al, 2017b) (Table I) .
ID is not unique to donors of RBC units. Plateletpheresis donors may be prone to iron depletion because of the increased donation frequency allowed (up to 24 times/year in the US) which results in a higher number of smaller RBC losses with each procedure (50-80 ml in samples and tubing), in individuals often recruited from the ranks of repeat whole blood donors. In one study, 34% of plateletpheresis donors had ID (F < 30 lg/l), and frequent donors (donating every 2 weeks) were twice as likely to be iron deficient (Page et al, 2010) . Nine per cent of male plateletpheresis donors had ID in another study using a F < 20 lg/l cut-off (Duggan et al, 2016) .
Important new information on the high frequency of ID in adolescent blood donors has surfaced from the US. Although average ferritin values of FT teen donors are equivalent to epidemiological norms (Centers for Disease Control and Prevention, 2012) , the prevalence of ID is greater in repeat teenage donors than adults (FDA 2016) . These findings have raised concerns because of the increasing proportion of teenage donations in the US blood supply (Bloch et al, 2017; Goldman et al, 2017a) and growing recognition of the role of iron metabolic pathways in neurocognitive development (Casey et al, 2011; Mills et al, 2014; Jahanshahad et al 2012) .
Predictive factors for iron depletion in blood donors have been identified in large observational studies and are important in initiating focused strategies to mitigate ID. In the REDS-II Donor Iron Status Evaluation (RISE) study, young female donors were 3-7 times more likely to have ferritin ≤12 lg/l than post-menopausal female or male donors. (Cable et al, 2012a) Controlling for demographic, behavioural and other factors, donation intensity stood out as the most important predictor by far, with those donating 10 or more times over the prior 2 years 19 times more likely to have F ≤ 12 lg/l than FT donors. Donation intensity and female sex were found to be the strongest independent predictors of low ferritin. Age, weight, smoking, HFE genotype, menstrual blood losses and pregnancy status were less associated. Waiting longer intervals between donations (at least 14 weeks) was associated with lower risk for low ferritin compared to donations made at shorter intervals, as was taking self-directed iron supplements alone or in combination with multivitamins (reported by 39%). Diet had little or no effect. In the Danish study of nearly 15 000 donors, ID (defined as F ≤ 15 lg/l) was strongly associated with female sex, menopausal status, blood donation frequency and the time since the previous donation. (Rigas et al, 2014) The risk of ID was only weakly associated with body weight, menstrual blood loss, and dietary and supplemental iron intake.
Assessment of iron status in blood donors
Serum ferritin levels in healthy blood donors are lessfrequently influenced by acute phase changes and provide a more reliable indication of true iron status than in clinical medicine (Kiss, 2015) . The capillary (fingerstick) Hb measurement prior to each donation is the only point-of-care screening test in use to qualify blood donors in nearly all countries around the world. Acceptance standards vary in different locales (Goldman et al, 2016a) . In the US and Canada the Hb must be ≥125 g/l in women and ≥130 g/l in men. The intent of the minimum Hb cut-off is to prevent collection of blood from anaemic donors (this is approximate; according to the World Health Organization (WHO), the lower range of normal Hb in women is 120 g/l), but does not prevent collection of blood from donors who are iron deficient (Baart et al, 2013) . Changes in RBC morphological indices, including mean corpuscular volume, mean corpuscular haemoglobin and mean corpuscular haemoglobin concentration, which are used clinically as part of the routine evaluation of anaemia, occur late in the development of iron depletion and correlate poorly with reduced iron levels (Alexander et al, 2000) . A variety of different laboratory tests, including serum iron/total iron-binding capacity (TIBC) (% transferrin saturation), ferritin, sTfR, sTfR/ferritin ratio, zinc (free erythrocyte) protoporphyrin and specialized RBC indices measured by laser light scatter, have been used in an ancillary or investigational manner (non-point-of-care) to assess the iron status of blood donors (Radtke et al, 2005; Baart et al, 2013; Kiss et al, 2013) . In our estimation, none of these have been shown to be as useful as serum or plasma ferritin (the latter approximately 5% lower than serum values) in monitoring and managing the iron status of blood donors.
Ferritin
Excess iron not directly utilized in physiological pathways is stored in tissues as ferritin, a large 24-subunit protein that retains elemental iron and releases it in a controlled fashion (Wang et al, 2010) . Small amounts of ferritin that circulate in blood are believed to be in passive equilibrium with cell and tissue ferritin. Normal population values are influenced by sex and age. Adult males age 20-60 have between 134 and 150 lg/l, females 20-59 years have between 32-53 lg/l; these values increase to an average of 86 lg/l after menopause (Centers for Disease Control and Prevention 2012). Although the "classic" cut-off value reflecting iron depletion, 12 lg/l, is recognized as a specific indicator of absent iron stores in the clinical setting (Hallberg et al, 1993) and in blood donors, (Punnonen & Rajam€ aki, 1999) this threshold value also failed to identify ID in over a third of blood donors (Radtke et al, 2005) . Clinical studies based primarily on bone marrow staining for iron found 15 lg/l to more accurately reflect iron deficiency anaemia, (Guyatt et al, 1992; Hallberg et al, 1993) and this value has been adopted by the WHO. However, studies employing sTfR, a truncated form of the transferrin receptor that is released into blood when early erythroid cells become iron-deprived, reveal a higher ferritin threshold, between 22 and 40 lg/l, to more reliably detect iron-deficient erythropoiesis and tissue iron deficency (Punnonen et al, 1997; Suominen et al, 1998) . A higher threshold for detecting incipient ID in blood donors seems more rational considering the ongoing blood losses in regular donors.
Based on "normal" reference ranges, some investigators have used ferritin cut-off values based on sex (e.g., 20 lg/l in females and 30 lg/l in males), however, the lower values in females are a reflection of the relatively high prevalence of undiagnosed ID in young women. As iron depletion advances to the stage of tissue ID, sTfR increases as ferritin levels reach the lower limit of detection. A study in which daily iron supplementation was given for 3 months found that 40% of young women, but none of the men, had evidence of subclinical ID based on elevated sTfR (Suominen et al, 1998) . After iron treatment in both sexes (which normalized sTfR in the women), the "iron-replete" reference range for ferritin increased, from 7-76 lg/l before, to 17-123 lg/l in women and 14-188 lg/l before to 22-203 lg/l in men. Hence, the lower limit for ferritin in iron-replete men and women are comparable, and support a single, unified threshold. Prospective, non-randomized studies have found that ferritin monitoring along with recommendations to delay donation, seek medical advice, and/or take iron supplements modestly reduces the frequency of anaemia, Hb deferrals and low ferritin, with some decrease in rates of donor return (O'Meara et al, 2011; Magnussen & Ladelund, 2015; Goldman et al, 2016b; Goldman et al, 2017b ) and appears to be feasible (Gorlin et al, 2016) . sTfR values have been used in conjunction with ferritin measurements as a ratio, log (sTfR/ferritin) (Skikne et al, 1990; Cook et al, 2003) . In the RISE study, a log (sTfR/ferritin) value of 2Á07 (97Á5% of the upper limit of the reference range in men) correlated with a ferritin level of 26Á7 lg/l by regression analysis, reflecting iron-deficient erythropoiesis in healthy blood donors . Ferritin at this threshold had 95Á1% sensitivity and 89Á6% specificity in identifying IDE. It was concluded that ferritin of 26 lg/l (rounded down) provided the simplest and best discriminatory value to be used in conjunction with the capillary Hb standard.
Hepcidin
Because of the pivotal role played in the regulation of iron homeostasis (Goodnough et al, 2010; Ganz & Nemeth, 2012) , hepcidin has also been of interest in evaluating iron status in blood donors. Hepcidin and ferritin levels correlate reasonably well with each other (in two studies, coefficients were 0Á66 (Pasricha et al, 2011) and 0Á74 ) and hepcidin levels compared similarly to other biomarkers such as sTfR, with a receiver operator characteristic (ROC) area of the curve (AUC ROC ) of 0Á87 (95% confidence interval 0Á82, 0Á92) using a ferritin cut-off of 15 lg/l as the threshold for ID (Pasricha et al, 2011) . Also similar to ferritin, the reported reference range is wide, 8Á2-199Á7 lg/l in non-iron depleted women. By ROC analysis, a hepcidin level of 8 ng/ mL had a sensitivity of only 41Á5% with specificity of 97Á6%, however, using a threshold of 18 ng/mL, sensitivity increased to 79Á2%, while maintaining a specificity of 85Á6%. Several studies have investigated the prediction of Hb and ferritin recovery after blood donation. Mast et al (2013) found an association between low hepcidin and Hb values (5Á0 g/l lower) in donors whose ferritin values were ≤26 lg/l. Waldvogel et al (2016) found no relationship between hepcidin levels at baseline and response to oral iron at 4 weeks in relation to ferritin and Hb, although hepcidin levels did increase in ferritin responders. Finally, Lotfi et al (2015) reported that in non-iron supplemented donors, those with a low hepcidin/ferritin ratio (<0Á30) regained 60% of initial ferritin at 56 days, while those with a higher ratio recovered <50% of baseline. Although more investigation is needed, it appears that individual differences in the hepcidin response may help explain at least some of the variation in iron and Hb recovery following repeated donations.
Mitigation of progressive ID in blood donors
As previously mentioned, recent well-designed cohort trials have characterized the magnitude of the risk of ID in a number of donor subgroups (Table I) (Cable et al, 2011; FDA 2016) . In addition, interventional trials have demonstrated a slow recovery of post-donation iron stores with diet alone or in combination with lengthening inter-donation intervals, their rapid repletion with iron supplements, and the effectiveness of strategies to educate/motivate donors about ways to prevent worsening ID Mast et al, 2016; Pasricha et al, 2017) . Armed with several strategies to intervene, it seems prudent to employ them in individuals at risk (Table II) , especially groups that are considered potentially more vulnerable to cognitive dysfunction that may or may not be reversible: young blood donors and the infants of female donors of childbearing potential. A reasonable initial step involves comprehensive donor education about iron balance and the risks of ID. AABB (formerly the American Association of Blood Banks) currently mandates that member blood collectors provide educational materials on the risks of post-donation ID (Ooley, 2016) . In a 2017 association bulletin, AABB has asked collectors to enhance materials to include the benefits of iron supplementation and provide specific recommendations on iron preparations, doses and duration, as well as the applicability of supplements in particular donor subgroups (AABB 2017). A 13-month Australian study in female donors of childbearing potential demonstrated that education alone did not prevent worsening Hb and ferritin values (Pasricha et al, 2017) . However, in the 26% of donors who purchased and took the majority of the recommended iron dose, post-donation iron stores were maintained.
The Hemoglobin Iron and Recovery Study (HEIRS) randomized 215 adult blood donors in a 24-week study of 37Á5 mg of elemental iron taken daily versus no supplements . The donors' venous Hb values recovered (pre-defined endpoint was ≥80% of pre-donation values) by a mean of 4-5 weeks in those on iron versus 11-23 weeks in those not taking supplements (Fig 4) . Iron stores (assessed by plasma ferritin) returned to baseline a median of 11 vs. >24 weeks with supplemental iron (Fig 5) . Indeed, twothirds of donors not taking iron had not attained pre-donation ferritin values by 24 weeks (Fig 6) . Analysis of the iron-treated donors (who received iron throughout the 24-week study period) revealed that at least 87% of iron repletion occurred within the first 8 weeks of iron therapy . Thus, daily low-dose iron for 56-60 days appears to be an effective strategy to replace iron lost during blood donation. On the other hand, extension of the interdonation interval would require at least 24-26 weeks to replenish iron stores on a regular diet Schotten et al, 2016) , at considerable detriment to critical blood inventories (Eder et al 2010) .
Another pivotal randomized, controlled trial (Strategies to Reduce Iron Deficiency, STRIDE) provided iron supplements at two doses (19 or 28 mg of elemental iron taken daily for 60 days), or an informational letter sharing plasma ferritin values with donors and recommending iron therapy or delay in subsequent donation in those with low iron stores, or continued donation for those with sufficient iron reserves . These 3 interventional arms were compared with a placebo pill and 'placebo letter' without ferritin Review values which simply recommended frequent donation. At the end of the study, Hb and ferritin were similar in the 3 interventional arms, and statistically lower in the placebo arms. Reductions of 30-80% in the prevalence of ID occurred only in the interventional arms. A longitudinal analysis revealed that iron status (measured by ferritin, sTfR and log(sTfR/ferritin)) improved significantly with iron pills, was slightly less improved with the interventional letter, but declined in the two placebo arms. One can conclude that 60 days of either 19 or 38 mg elemental iron are equally efficacious, and that ferritin testing was effective and mostly equivalent to iron in replacing lost iron stores. The majority of those provided with low ferritin test results chose to take an iron supplement rather than delay donating, again pointing to exogenous iron as the main contributor to the salutary effect associated with being informed of ferritin status .
Accordingly, AABB and others in North America have recommended that blood collectors implement an effective strategy to mitigate donation-induced ID. These may include blood collector-facilitated access to iron supplements, meaningful extension of the inter-donation interval, or When looked at as % of baseline, on average there is~10% removal of RBC mass with each donation (~8% in men, 12% in women). Hb recovery was 6% higher than baseline in the low-ferritin group (≤26 lg/l) who took iron (P < 0Á001) and 1Á9% lower than baseline in the higher-ferritin group (>26 lg/l) who took no iron (P = 0Á02). Dotted line indicates 100% of initial Hb value; error bars, 95% confidence intervals (CI). Adapted with permission from JAMA. 2015. 313(6): 575-83. Copyright©2015 American Medical Association. All rights reserved. (Table II) .
For iron supplementation, a dose of 18-38 mg of oral elemental iron for 60 days is recommended. This can be provided as a supplement or as a multivitamin with iron, and be directly distributed to the donor or provided as a voucher redeemable for pills to facilitate the donor's acquisition of iron. The recommended doses are derived from the most commonly-available dose in multivitamin with iron preparations, which is similar to the lowest effective dose in STRIDE, and the Institute of Medicine's maximum tolerable dose of 45 mg (above which adverse effects exceed those of placebo) (Institute of Medicine 2001). The logistics of maintaining a voucher program or obtaining and distributing iron pills are complex and there may be some jurisdictional issues to overcome for blood collectors to dispense iron. Other challenges include the identification of individuals who may not be appropriate candidates for iron, including those with a personal or family history of heritable iron overload syndromes, gastrointestinal polyposis or cancer, inflammatory bowel disease or on medications whose absorption is impaired by iron. The facilitated provision of iron however, has been demonstrated to be effective in maintaining Hb and ferritin concentrations, with a reduction in ID (Magnussen & Ladelund, 2015; Pasricha et al, 2017) . Approximately 75% of donors took at least three-quarters of directly provided iron (at doses above those associated with side effects) in the Australian DIRECT study (Pasricha et al, 2017) . Whether vouchers for discounted or free low dose supplements would be associated with similar rates of compliance in a non-study donor population is unknown. However, blood donors in Denmark monitored by a centrally organized "donor haemoglobin and iron resource team," who were provided iron supplements based on Hb and selective ferritin testing were shown to increase Hb levels and reduce Hb deferrals (from 0Á9% to 0Á3% in men, and 3Á9% to 2Á7% in women) over a 2-year follow-up period (Magnussen & Ladelund, 2015) , and a remarkable reduction in low hemoglobin deferrals (Smith et al, 2014) that represents a "win-win" for both the donor and maintaining adequate blood inventories. A careful approach to iron replacement is indicated in donors at risk for GIpathology. A study providing 19 or 38 mg of iron for 60 days over 2 years of donation observed a 3-4 g/l mean increase in donor Hb . In irondepleted individuals, this rise is likely to be greater and could blunt the anaemia leading to a diagnosis of GI malignancy. The British Society of Gastroenterology has published guidelines that advocate questioning for blood donation as a source of Hb loss and stipulate under what circumstances GI endoscopy should be undertaken for IDA or NAID in blood donors (Goddard et al, 2011) .
Lengthening of the inter-donation interval is another recommended measure to avoid progressive iron depletion. However, this approach is highly unlikely to be effective as a solitary intervention to mitigate donor ID, as the interval must be lengthened to more than 24 weeks, resulting in a maximum of once-or twice-annual donation. The resultant loss of collections must be offset by aggressive expansion of the donor base to avoid a potentially serious shortage of available blood products . In addition, this approach does not shorten post-donation periods of ID, which may pose continued risk in vulnerable donor subgroups, such as adolescents.
There is no approved, rapid, inexpensive pre-donation ferritin test currently available in the US. As such, ferritin testing is limited to samples obtained during blood donation, with results available several days later. Ferritin testing involves additional costs for testing, computer enhancements, and donor notification/counselling. As a means of informing donors of their iron status to motivate ID-mitigating action though, it has been shown to be effective in mitigating donor iron depletion. However, outside of a research setting, donor compliance with recommendations to take iron or extend inter-donation intervals is not fully known. Ferritin testing also directly assesses iron status and can inform donors with high-normal values of the absence of the immediate need to take iron or change donation patterns. It can also identify pre-existing ID in first-time donors, and lead to collaborative interactions with healthcare providers. The serial observation of low ferritin values may indicate donors in need of additional communication or perhaps mandated inter-donation interval extension.
Of note, iron loss occurs with apheresis platelet or plasma donation, albeit at a rate one-quarter to one-fifth that of whole blood donation. As such, apheresis donors merit consideration for all the previous interventions, at a schedule appropriate to iron losses equivalent to the~250 mg in a whole blood donation. In jurisdictions that allow double RBC donation, more iron must be replaced. The optimum duration of iron supplementation is uncertain; although one might empirically choose 120 days of 19-38 mg elemental iron to replenish the "double" unit loss, the additional haematopoietic stimulus may enhance fractional iron absorption and shorten the time needed. Likewise, although the current required inter-donation interval for double RBC donations in the US is 112 days, the necessary duration to fully replenish lost iron stores without supplements is not known.
One blood collector's approach
Blood Systems initiated a pilot programme across a number of its centres in November2012 to inform blood donors with borderline Hb values (females 125-129 g/l, males 125-134 g/ l) of low ferritin levels in an effort to promote iron health and decrease Hb deferrals. Serum ferritin was assessed from successful donors' diversion pouch tubes required for infectious disease testing. Donors with F < 12 lg/l (a value representing absent iron stores (AIS)) were informed by letter of their ferritin value, deferred from donation for 24 weeks, and counselled to see their physician if they were infrequent donors. Individuals with values between 12 lg/l and either 19Á9 lg/l for females or 29Á9 lg/l for males (values representing iron-deficient erythropoiesis (IDE)) were initially deferred from RBC-containing, but not apheresis platelet or plasma donations, and within 6 months of implementation were no longer being deferred. Approximately 6% of male and 16% of female whole blood and apheresis donors were tested in the first 4 months. Of tested male donors, 26% had AIS and 28% IDE (Custer et al, 2013) . For females, 31% had AIS and 22% IDE. Over time with changing deferrals, testing decreased so that by 13 months, 5% of males and 13% of females required testing based on their Hb values. Akin to findings in the CHILL study, AIS and IDE were more prevalent in 16-to 19-year-old female donors and IDE in male donors of high-school age than older donors (Bravo et al, 2014 , FDA 2016 . Of donors notified of low ferritin values, 71% returned within 12 months of their deferral expiration, while 82% of non-deferred donors returned within 12 months (Kamel et al, 2016) . Donors returning after a 24-week delay had a significantly higher Hb than those presenting within 24 weeks. Unpublished data showed that low Hb deferral rates from identical 22-month periods before and after implementation of ferritin testing declined from 1Á5% to 0Á9% (a 40% relative decline) for male donors and 12Á0% to 10Á3% (a 14% relative decline) for females. As data accumulated on ID in young donors and concern for iron health shifted, Blood Systems centres' focus has transitioned from borderline Hb donors to young donors. Paused in June 2015, its one-of-a-kind ferritin monitoring safety initiative was modified to protect adolescent donors and reinitiated in December 2016. All successfully drawn 16-to 18-year-old donors had serum ferritin testing from diversion pouch tubes. By July 2017, almost 50 000 donors had been tested, representing 10Á0% of all donations made within this period (a maximum of 16Á0% of donations in April to a minimum of 2Á5% in June). Female teens with ferritin values <20 lg/l were notified by letter, counselled to take 18-28 mg of elemental iron daily for 60 days, and deferred from RBCcontaining donations for 12 months. Male teens with ferritin values <30 lg/l were similarly notified and counselled, and deferred for 6 months. Of tested donors, 28Á8% had low ferritin; 18Á4% of males had F < 30 lg/l and 38Á8% of females had F < 20 lg/l. One per 3550 donors, 86% of whom were male, had F > 450 lg/l (the limit of assay linearity), and were notified to consult a physician for further testing for hereditary haemochromatosis or other conditions resulting in high ferritin values. Blood Systems centres continue to assay teen donor ferritin levels, but have not yet determined the impact of mandated extension of inter-donation intervals on donor return or deferral rates. Consideration has been given to providing iron vouchers to donors with IDE, deferring only those with significant AIS. Issues surrounding minor guardian consent and jurisdictional practice-of-medicine rules in the US have delayed implementation of program changes.
The role of healthcare providers in blood donor iron homeostasis
Recommendations for ID screening vary by professional society. Most recommend anaemia screening and follow-up iron status testing in young children and pregnant women, but do not currently advocate investigation for NAID (American College of Obstetricians & Gynecologists, 2008; Pavord et al, 2012; Siu; U.S. Preventive Services Task Force, 2015) . The US Centers for Disease Control and Prevention also recommends that beginning in adolescence, all non-pregnant premenopausal women should be screened periodically for anaemia or annually in those at increased risk for ID with extensive menstrual or other blood loss, low iron intake or a previous diagnosis of IDA, and screening for 16-to 18-yearold boys with a history of IDA, special health-care needs, or low iron intake (Centers for Disease Control and Prevention 1998). The American Academy of Pediatrics also recommends anaemia screening (Wu et al, 2002) . Of note, none of these organizations currently call out routine blood donation as a risk factor to prompt anaemia screening and/or iron studies in non-anaemic individuals, despite the known increased risk for ID and IDA in young and/or frequent blood donors.
Conclusions and outlook
Blood collectors have a dual responsibility, both to ensure donor health and safety, while also assuring the adequacy of the blood supply for the many patients in need of transfusion therapy. As we look toward the mitigation of ID in (Table II) , blood centres will require the support of professional societies to communicate this initiative to practicing clinicians and pharmacists. Low dose iron taken for short periods has been shown to be both well-tolerated by donors and feasible. However, blood collectors and blood donors must rely on healthcare providers for advice about the individual appropriateness of low dose iron in some instances, e. g., evaluating side effects, potential drug interactions (Campbell & Hasinoff, 1991) , and the investigation and treatment of donors who are repeatedly deferred for low hgb and/or anaemia that does not improve with iron supplements. Healthcare providers should be familiar with guidelines on when to undertake GI endoscopy and just as importantly, when not to do so (Goddard et al, 2011) . Without awareness in the wider healthcare arena, donors may be subjected to potentially mixed messages and lose their motivation to donate, and/or not receive optimal care.
Over the next few years we expect to see programmes implement one or more strategies that will impact donor iron status, including low dose iron supplementation, ferritin testing with donor action in response to knowledge of iron status, and/or lengthening the inter-donation interval. The donor risk stratification is fairly clear, with adolescent donors, pre-menopausal females, and frequent donors, in that order, being the most susceptible to the potential harms of ID. To us, mitigation simply means replacing all or most of the iron that the altruistic blood donor has lost, with improvement over time as we see donor ferritin levels rising (when measured) and Hb deferrals decreasing. Scientific and operational studies have enabled this opportunity to improve donor health and well-being, hopefully with limited impact on the blood inventories relied on by patients throughout the world.
